Brief Summary
This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
Brief Title
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis
Detailed Description
Subjects ages 18-75 with primary biliary cholangitis will be screened up to 14 days prior to enrollment into the study. Screening will be completed to assess eligibility, obtain vital signs, collect laboratory samples and PD measurements, and to receive a FibroScan for liver fibrosis. Subjects will additionally complete an initial PBC-40 assessment and begin an Itch Diary, a questionnaire and scoring system to be completed by the patient every morning and evening through Day 120 and then monthly through end of study.
Subjects who meet all inclusion and no exclusion criteria after completing the screening visit will be enrolled in the study. Subjects will be randomized on Day 1 in a 1:1 ratio to receive either CNP-104 or Placebo (0.9% Sodium Chloride USP) by intravenous (IV) infusion. Subjects will be administered CNP-104 or Placebo on Day 1 and on Day 8. This study was originally designed with 2 cohorts, Cohort 1 comprised of 6 subjects randomized 1:1 to placebo or 4 mg/kg, and Cohort 2 comprised of up to 34 subjects randomized 1:1 to placebo or 8 mg/kg. Under Protocol Amendment 6 (v7.0), the remaining subjects for Cohort 2 (approximately 16) will be randomized 1:3:1 to placebo, 4 mg/kg, and 8 mg/kg respectively.
Subjects will remain in the clinic on Day 1 and Day 8 from the time of admission (prior to administration of CNP-104 or Placebo) through the final procedure conducted 4 hours post-dose that same day unless an infusion reaction, or other adverse event, requires an extended duration of monitoring. Subjects will be discharged if safety parameters are acceptable to the investigator.
Seven days after the second administration of CNP-104 or Placebo, subjects must return to the clinic for collection of safety labs, PD measurements, and assessment of AEs and medication changes.
Subjects will continue to be followed for 2 years to assess safety, pharmacodynamics, and immunogenicity during the Post-Dosing period.
Subjects who meet all inclusion and no exclusion criteria after completing the screening visit will be enrolled in the study. Subjects will be randomized on Day 1 in a 1:1 ratio to receive either CNP-104 or Placebo (0.9% Sodium Chloride USP) by intravenous (IV) infusion. Subjects will be administered CNP-104 or Placebo on Day 1 and on Day 8. This study was originally designed with 2 cohorts, Cohort 1 comprised of 6 subjects randomized 1:1 to placebo or 4 mg/kg, and Cohort 2 comprised of up to 34 subjects randomized 1:1 to placebo or 8 mg/kg. Under Protocol Amendment 6 (v7.0), the remaining subjects for Cohort 2 (approximately 16) will be randomized 1:3:1 to placebo, 4 mg/kg, and 8 mg/kg respectively.
Subjects will remain in the clinic on Day 1 and Day 8 from the time of admission (prior to administration of CNP-104 or Placebo) through the final procedure conducted 4 hours post-dose that same day unless an infusion reaction, or other adverse event, requires an extended duration of monitoring. Subjects will be discharged if safety parameters are acceptable to the investigator.
Seven days after the second administration of CNP-104 or Placebo, subjects must return to the clinic for collection of safety labs, PD measurements, and assessment of AEs and medication changes.
Subjects will continue to be followed for 2 years to assess safety, pharmacodynamics, and immunogenicity during the Post-Dosing period.
Categories
Completion Date
Completion Date Type
Estimated
Conditions
Primary Biliary Cholangitis
Eligibility Criteria
Inclusion Criteria:
1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant women, ages 18-75 years inclusive.
3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:
1. Alkaline phosphatase \> 1.5× ULN for at least 6 months
2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\])
3. Liver biopsy findings consistent with PBC
4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN.
5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
6. Subjects with ALP \> 1.5× ULN.
7. Subjects with AST and ALT \< 5× ULN.
8. Subjects with hemoglobin ≥ 10 g/dL.
9. Subjects with total bilirubin \< 2× ULN.
10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
12. Male subjects who agree to not donate sperm starting at screening and through Day 90.
Exclusion Criteria:
1. Subjects with a Class B or Class C Child-Pugh score.
2. Subjects with concomitant liver diseases including chronic viral hepatitis B or C, autoimmune hepatitis, PSC, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's syndrome.
3. Subjects who have previously undergone liver transplantation.
4. Subjects with decompensated liver disease as defined by the presence or history of any of the following:
* MELD score \> 15
* Hepatic encephalopathy
* Ascites
* Hepatorenal syndrome or serum creatinine \> 2 mg/dL
* Total Bilirubin \> 3.0 mg/dL
* INR \>1.8 unless on anticoagulation such as Coumadin
* History of variceal hemorrhage
5. Subjects with a history of cerebrovascular accident in the past 12 months.
6. Subjects with history of myocardial infarction, as defined by any of the following criteria:
* Development of pathological Q waves with or without symptoms
* Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause
* Pathological findings of a healed or healing myocardial
7. Subjects with chronic kidney disease, as defined by estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 for at least 3 months (per CKD EPI Equation - 2021).
8. Subjects with uncontrolled diabetes, as defined by HbA1c \> 7%.
9. Subjects who have used the following medications:
* Methotrexate within 90 days of screening.
* Immunotherapy drugs unless approved by the medical monitor.
10. Subjects with a history of tuberculosis or positive PPD skin test.
11. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to screening or are planning to receive any vaccination before Day 90.
12. Subjects who have used systemic steroids within 3 months prior to screening.
13. Subjects with laboratory test results at screening or prior to study dosing that are outside the normal limits and considered by the Investigator to be clinically significant.
Note: This criterion does not apply to liver function tests. Additionally, clinically significant laboratory test results at screening that are related to the condition (PBC) are acceptable as long as all inclusion and no other exclusion criteria are met.
14. Subjects with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at screening.
15. Subjects with a history of or currently active immune disorders other that PBC (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
16. Subjects with a history of or current active diseases requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
17. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.
18. Subjects with a complication or medical history of malignancy within past 5 years which, in the Investigator's opinion, makes the subject unsuitable for study participation.
19. Subjects who, in the Investigator's opinion, will be unable to adhere to study procedures.
20. Subjects who have received an investigational therapy other than CNP-104 within 28 days or 5 half-lives, whichever is longer, prior to screening.
21. Subjects with any condition which, in the Investigator's opinion, makes the subject unsuitable for study participation.
22. Known sensitivity to any components of CNP-104.
1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant women, ages 18-75 years inclusive.
3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:
1. Alkaline phosphatase \> 1.5× ULN for at least 6 months
2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\])
3. Liver biopsy findings consistent with PBC
4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN.
5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
6. Subjects with ALP \> 1.5× ULN.
7. Subjects with AST and ALT \< 5× ULN.
8. Subjects with hemoglobin ≥ 10 g/dL.
9. Subjects with total bilirubin \< 2× ULN.
10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
12. Male subjects who agree to not donate sperm starting at screening and through Day 90.
Exclusion Criteria:
1. Subjects with a Class B or Class C Child-Pugh score.
2. Subjects with concomitant liver diseases including chronic viral hepatitis B or C, autoimmune hepatitis, PSC, alcoholic liver disease, Wilson's disease, hemochromatosis, or Gilbert's syndrome.
3. Subjects who have previously undergone liver transplantation.
4. Subjects with decompensated liver disease as defined by the presence or history of any of the following:
* MELD score \> 15
* Hepatic encephalopathy
* Ascites
* Hepatorenal syndrome or serum creatinine \> 2 mg/dL
* Total Bilirubin \> 3.0 mg/dL
* INR \>1.8 unless on anticoagulation such as Coumadin
* History of variceal hemorrhage
5. Subjects with a history of cerebrovascular accident in the past 12 months.
6. Subjects with history of myocardial infarction, as defined by any of the following criteria:
* Development of pathological Q waves with or without symptoms
* Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause
* Pathological findings of a healed or healing myocardial
7. Subjects with chronic kidney disease, as defined by estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 for at least 3 months (per CKD EPI Equation - 2021).
8. Subjects with uncontrolled diabetes, as defined by HbA1c \> 7%.
9. Subjects who have used the following medications:
* Methotrexate within 90 days of screening.
* Immunotherapy drugs unless approved by the medical monitor.
10. Subjects with a history of tuberculosis or positive PPD skin test.
11. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to screening or are planning to receive any vaccination before Day 90.
12. Subjects who have used systemic steroids within 3 months prior to screening.
13. Subjects with laboratory test results at screening or prior to study dosing that are outside the normal limits and considered by the Investigator to be clinically significant.
Note: This criterion does not apply to liver function tests. Additionally, clinically significant laboratory test results at screening that are related to the condition (PBC) are acceptable as long as all inclusion and no other exclusion criteria are met.
14. Subjects with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at screening.
15. Subjects with a history of or currently active immune disorders other that PBC (including autoimmune disease) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
16. Subjects with a history of or current active diseases requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the Medical Monitor, has been deemed to be acceptable for the subject's participation in this study.
17. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator.
18. Subjects with a complication or medical history of malignancy within past 5 years which, in the Investigator's opinion, makes the subject unsuitable for study participation.
19. Subjects who, in the Investigator's opinion, will be unable to adhere to study procedures.
20. Subjects who have received an investigational therapy other than CNP-104 within 28 days or 5 half-lives, whichever is longer, prior to screening.
21. Subjects with any condition which, in the Investigator's opinion, makes the subject unsuitable for study participation.
22. Known sensitivity to any components of CNP-104.
Inclusion Criteria
Inclusion Criteria:
1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant women, ages 18-75 years inclusive.
3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:
1. Alkaline phosphatase \> 1.5× ULN for at least 6 months
2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\])
3. Liver biopsy findings consistent with PBC
4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN.
5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
6. Subjects with ALP \> 1.5× ULN.
7. Subjects with AST and ALT \< 5× ULN.
8. Subjects with hemoglobin ≥ 10 g/dL.
9. Subjects with total bilirubin \< 2× ULN.
10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
12. Male subjects who agree to not donate sperm starting at screening and through Day 90.
inclusion and no
1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations.
2. Men and non-pregnant women, ages 18-75 years inclusive.
3. Subjects with a PBC diagnosis as demonstrated by the presence of 2 or more of the following 3 diagnostic factors:
1. Alkaline phosphatase \> 1.5× ULN for at least 6 months
2. Positive AMA titer or, if AMA negative or in low titer (\<1:40), positive PBC-specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\])
3. Liver biopsy findings consistent with PBC
4. Subjects who are unresponsive to UDCA and/or OCA after 6 months of treatment at a stable dose as measured by ALP \> 1.5× ULN.
5. For subjects on any medication used to treat the symptoms of PBC (ex. UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 3 months prior to enrollment and must agree not to change their dose through study Day 60 unless reviewed by the medical monitor and approved by the site investigator.
6. Subjects with ALP \> 1.5× ULN.
7. Subjects with AST and ALT \< 5× ULN.
8. Subjects with hemoglobin ≥ 10 g/dL.
9. Subjects with total bilirubin \< 2× ULN.
10. Men and women of child-bearing potential (WOCBP) must agree to practice a highly effective method of contraception that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD) beginning at the time of screening through Day 90.
11. Female subjects who agree not to donate ova starting at initial screening and through Day 90.
12. Male subjects who agree to not donate sperm starting at screening and through Day 90.
inclusion and no
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
75 Years
Minimum Age
18 Years
NCT Id
NCT05104853
Org Class
Industry
Org Full Name
COUR Pharmaceutical Development Company, Inc.
Org Study Id
CNP-104-5.001
Overall Status
Active, not recruiting
Phases
Phase 1
Phase 2
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
Primary Outcomes
Outcome Description
Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to discontinuation from TP and study, by severity, and by causality. No formal statistical testing will be done
Outcome Measure
Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Outcome Time Frame
through Study Completion, an average of 720 Days
Outcome Description
Frequency tables of each assessment abnormalities by grade and treatment will be presented. No formal statistical testing will be done.
Outcome Measure
Laboratory safety assessments (hematology, serum chemistry, coagulation panel, urinalysis).
Outcome Time Frame
through Study Completion, an average of 720 Days
Outcome Description
Frequency tables will be presented by treatment group. No formal statistical testing will be done
Outcome Measure
Serum Cytokines (TNF-α, IL-4, IL-6, IL-10, IL-1β, MCP-1, MIP-1α, IFN-γ)
Outcome Time Frame
through CNP-Dosing Period, an average of 15 Days
Secondary Outcomes
Outcome Description
Change from baseline in ALP levels at Day 60 and Day 720
Outcome Time Frame
through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change from baseline in Serum Alkaline Phosphatase (ALP) levels, for safety only
Outcome Description
Change from baseline in AMA between placebo and CNP-104 at Day 90 and Day 720
Outcome Time Frame
through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change from baseline in AMA
Outcome Description
Change from baseline in liver fibrosis by FibroScan between placebo and CNP-104 at Day 90 and Day 720
Outcome Time Frame
through Visit 7, an average of 90 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change from baseline in liver fibrosis by FibroScan
Outcome Description
Change from baseline in modified PBC-40 score between placebo and CNP-104 at Day 60 and Day 720
Outcome Time Frame
through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change from baseline in modified PBC-40 score
Outcome Description
Change from baseline in Weekly Mean Itch Score between placebo and CNP-104 at Day 60 and Day 720
Outcome Time Frame
through Visit 6, an average of 60 Days and Visit 16, an average of 720 D
Outcome Measure
To assess the change from baseline in Weekly Mean Itch Score
Outcome Description
Change from baseline in liver enzymes at Days 60 and 720
Outcome Time Frame
through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change from baseline in liver enzymes (Albumin, Bilirubin (total and direct), ALT, AST, GGT)
Outcome Description
Change from baseline in antigen specific CD4+ and CD8+ T at Days 60 and 720
Outcome Time Frame
through Visit 6, an average of 60 Days and Visit 16, an average of 720 Days
Outcome Measure
To assess the change in antigen specific CD4+ and CD8+ T cells
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Actual
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
75
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Brett Fortune
Investigator Email
bfortune@montefiore.org